← Back to Calendar
Indication
Hemolytic disease of the fetus and newborn (HDFN)
Key Notes
Anti-FcRn antibody for the prevention of HDFN. Rare pregnancy complication.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Advertisement